On Tuesday, Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) was 11.82% up from the session before settling in for the closing price of $585.31. A 52-week range for REGN has been $476.49 – $943.27.
During the last 5-year period, the sales growth of Healthcare Sector giant was 15.74%. When this article was written, the company’s average yearly earnings per share was at -7.14%. With a float of $102.14 million, this company’s outstanding shares have now reached $104.60 million.
Regeneron Pharmaceuticals, Inc (REGN) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Regeneron Pharmaceuticals, Inc stocks. The insider ownership of Regeneron Pharmaceuticals, Inc is 3.63%, while institutional ownership is 85.75%. The most recent insider transaction that took place on Nov 01 ’24, was worth 844,610. In this transaction EVP Commercial of this company sold 1,000 shares at a rate of $844.61, taking the stock ownership to the 12,931 shares. Before that another transaction happened on Nov 01 ’24, when Company’s Officer proposed sale 1,000 for $844.61, making the entire transaction worth $844,610.
Regeneron Pharmaceuticals, Inc (REGN) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted 12.07 earnings per share (EPS) during the time that was better than consensus figure (set at 11.19) by 0.88. Wall Street market experts anticipate that the next fiscal year will bring earnings of 10.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.20% during the next five years compared to 15.74% growth over the previous five years of trading.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Trading Performance Indicators
You can see what Regeneron Pharmaceuticals, Inc (REGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.88. Likewise, its price to free cash flow for the trailing twelve months is 18.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 39.69, a number that is poised to hit 10.42 in the next quarter and is forecasted to reach 42.71 in one year’s time.
Technical Analysis of Regeneron Pharmaceuticals, Inc (REGN)
Looking closely at Regeneron Pharmaceuticals, Inc (NASDAQ: REGN), its last 5-days average volume was 1.14 million, which is a jump from its year-to-date volume of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 84.01%.
During the past 100 days, Regeneron Pharmaceuticals, Inc’s (REGN) raw stochastic average was set at 99.29%, which indicates a significant increase from 98.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 17.04 in the past 14 days, which was higher than the 16.08 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $578.02, while its 200-day Moving Average is $597.03. However, in the short run, Regeneron Pharmaceuticals, Inc’s stock first resistance to watch stands at $671.78. Second resistance stands at $689.07. The third major resistance level sits at $722.45. If the price goes on to break the first support level at $621.11, it is likely to go to the next support level at $587.73. Now, if the price goes above the second support level, the third support stands at $570.44.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Key Stats
There are 105,987K outstanding shares of the company, which has a market capitalization of 69.37 billion. As of now, sales total 14,202 M while income totals 4,413 M. Its latest quarter income was 3,676 M while its last quarter net income were 1,392 M.
